RxDoctor Payments Data

Deshawntae Griffin

Psychiatric/Mental Health · Milwaukee, WINPI 1649810938

Payments from drug & device makers

$1,640in general payments, 2019–2025

Across 45 payments — averaging $36.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$610
  • Otsuka America Pharmaceutical, Inc.$271
  • Lundbeck LLC$243
  • Vanda Pharmaceuticals Inc.$157
  • Tris Pharma Inc$138
  • Novo Nordisk$135
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$1,640100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,640 in reported general payments places this provider in the 75th percentile of 384 psychiatric/mental health providers in Wisconsin.

See all psychiatric/mental health providers in Wisconsin

Medicare billing

Part B allowed, 2024
$15,238
Medicare patients
39
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$115,632
VraylarCariprazine Hcl65$96,885
AustedoDeutetrabenazine13$61,146
RexultiBrexpiprazole26$35,545
VivitrolNaltrexone Microspheres12$19,801
Lurasidone Hcl35$17,282
MydayisDextroamphetamine/Amphetamine12$4,548
Buspirone Hcl199$3,306
Aripiprazole145$3,090
Divalproex Sodium ErDivalproex Sodium58$2,967
Atomoxetine Hcl35$2,828
Vilazodone Hcl24$2,606
Risperidone159$2,459
Hydroxyzine Hcl104$2,248
Olanzapine127$2,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$610$96,88565 claims
Teva Pharmaceuticals USA, Inc.Austedo$22$61,14613 claims
Otsuka America Pharmaceutical, Inc.Rexulti$271$35,54526 claims
Lilly USA, LLCOlanzapine$21$2,213127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 384 psychiatric/mental health providers in Wisconsin.

Other psychiatric/mental health in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →